Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 36 articles: HTML format

Single Articles

September 2025
1. TSIRIZANI L, Waalewijn H, Szubert A, Mulenga V, et al
   Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV.
   Antimicrob Agents Chemother. 2025 Sep 26:e0077125. doi: 10.1128/aac.00771.
   PubMed     Abstract available
   
   
   
2. WANG C, Huang H, Valera L, Parcella K, et al
   Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499.
   Antimicrob Agents Chemother. 2025 Sep 3:e0030925. doi: 10.1128/aac.00309.
   PubMed     Abstract available
   
   
   August 2025
3. LAI Y-T, Dingens AS, DeMouth M, Helmold Hait S, et al
   Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.
   Antimicrob Agents Chemother. 2025 Aug 27:e0191024. doi: 10.1128/aac.01910.
   PubMed     Abstract available
   
   
   July 2025
4. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
   Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
   Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
   PubMed     Abstract available
   
   
   
5. LEONE PA, Losos J, Wannamaker P, D'Agostino R, et al
   VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results.
   Antimicrob Agents Chemother. 2025 Jul 23:e0025825. doi: 10.1128/aac.00258.
   PubMed     Abstract available
   
   
   
6. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
   Correction for Raines et al., "Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets".
   Antimicrob Agents Chemother. 2025 Jul 21:e0081725. doi: 10.1128/aac.00817.
   PubMed    
   
   
   
7. CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
   Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
   Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
   PubMed     Abstract available
   
   
   June 2025
8. FERNANDEZ-GONZALEZ M, Telenti G, Ledesma C, Losada-Echeberria M, et al
   Influence of patient characteristics and oral lead-in on long-acting cabotegravir and rilpivirine pharmacokinetics and outcomes in people with HIV: a real-world study.
   Antimicrob Agents Chemother. 2025 Jun 5:e0014525. doi: 10.1128/aac.00145.
   PubMed     Abstract available
   
   
   April 2025
9. MARGOLIS D, Watkins M, Zhu Y
   Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.
   Antimicrob Agents Chemother. 2025 Apr 22:e0020025. doi: 10.1128/aac.00200.
   PubMed     Abstract available
   
   
   
10. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    PubMed     Abstract available
    
    
    March 2025
11. MATTHEWS RP, Patel M, Liu W, Liu Y, et al
    Pharmacokinetics of islatravir in participants with moderate hepatic impairment.
    Antimicrob Agents Chemother. 2025 Mar 5:e0155324. doi: 10.1128/aac.01553.
    PubMed     Abstract available
    
    
    February 2025
12. LAZZARO A, Recchia GE, Alessi F, Santinelli L, et al
    Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.
    Antimicrob Agents Chemother. 2025 Feb 18:e0081524. doi: 10.1128/aac.00815.
    PubMed     Abstract available
    
    
    January 2025
13. FILLGROVE KL, Matthews RP, Lu B, Liang Y, et al
    Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravir.
    Antimicrob Agents Chemother. 2025 Jan 14:e0103024. doi: 10.1128/aac.01030.
    PubMed     Abstract available
    
    
    December 2024
14. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    PubMed     Abstract available
    
    
    October 2024
15. HAN K, D'Amico RD, Spreen WR, Ford SL, et al
    Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.
    Antimicrob Agents Chemother. 2024 Oct 23:e0088024. doi: 10.1128/aac.00880.
    PubMed     Abstract available
    
    
    September 2024
16. MARZINKE MA, Han K, Hanscom B, Guo X, et al
    Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
    Antimicrob Agents Chemother. 2024 Sep 23:e0099424. doi: 10.1128/aac.00994.
    PubMed     Abstract available
    
    
    
17. SHIN Y, Park CM, Kim D-E, Kim S, et al
    Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.
    Antimicrob Agents Chemother. 2024 Sep 4:e0064324. doi: 10.1128/aac.00643.
    PubMed     Abstract available
    
    
    
18. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
    Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
    PubMed     Abstract available
    
    
    August 2024
19. ZANG X, Ankrom W, Kraft WK, Vargo R, et al
    Intracellular islatravir-triphosphate half-life supports extended dosing intervals.
    Antimicrob Agents Chemother. 2024 Aug 6:e0045824. doi: 10.1128/aac.00458.
    PubMed     Abstract available
    
    
    July 2024
20. BAE J, Tantawy M, Gong Y, Langaee T, et al
    Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Antimicrob Agents Chemother. 2024 Jul 30:e0054924. doi: 10.1128/aac.00549.
    PubMed     Abstract available
    
    
    
21. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    PubMed     Abstract available
    
    
    
22. GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
    Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
    Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
    PubMed     Abstract available
    
    
    
23. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
    Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".
    Antimicrob Agents Chemother. 2024 Jul 2:e0081924. doi: 10.1128/aac.00819.
    PubMed    
    
    
    
24. MATTHEWS RP, Liu Y, Matthews C, Butterfield KL, et al
    Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults.
    Antimicrob Agents Chemother. 2024 Jul 2:e0046424. doi: 10.1128/aac.00464.
    PubMed     Abstract available
    
    
    June 2024
25. DIAMOND TL, Goh SL, Ngo W, Rodriguez S, et al
    No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.
    Antimicrob Agents Chemother. 2024 Jun 12:e0033424. doi: 10.1128/aac.00334.
    PubMed     Abstract available
    
    
    
26. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    PubMed     Abstract available
    
    
    
27. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
    Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.
    Antimicrob Agents Chemother. 2024 Jun 3:e0020124. doi: 10.1128/aac.00201.
    PubMed     Abstract available
    
    
    May 2024
28. PANJASAWATWONG N, Avihingsanon A, Menetrey C, Ribeiro I, et al
    Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
    Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008.
    PubMed     Abstract available
    
    
    
29. BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
    Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
    Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
    PubMed     Abstract available
    
    
    
30. HAN K, Patel P, McCallister S, Rinehart AR, et al
    Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
    Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475.
    PubMed     Abstract available
    
    
    April 2024
31. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    PubMed     Abstract available
    
    
    
32. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    PubMed     Abstract available
    
    
    March 2024
33. COSSU MV, D'Avolio A, Gervasoni C, Giacomelli A, et al
    Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Antimicrob Agents Chemother. 2024 Mar 27:e0017524. doi: 10.1128/aac.00175.
    PubMed    
    
    
    
34. HAN K
    Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Antimicrob Agents Chemother. 2024 Mar 27:e0020424. doi: 10.1128/aac.00204.
    PubMed    
    
    
    
35. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    PubMed     Abstract available
    
    
    
36. JOGIRAJU V, Weber E, Hindman J, West S, et al
    Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
    Antimicrob Agents Chemother. 2024 Mar 8:e0134423. doi: 10.1128/aac.01344.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.